Description: Kolon Life Science Inc. provides biopharmaceuticals, active pharmaceutical ingredients, pyrithione antimicrobials, and water solutions primarily in South Korea. Its biopharmaceutical product under development comprise KLS-1020, a cancer vaccine; KLS-3021, a oncolytic viral therapy; and KLS-2031 for treatment for neuropathic pain. The company also provides active pharmaceutical ingredients for anti-cancer and intermediates; and pyrithione antimicrobial for shampoo and soap bars, cosmetic and wet wipes, fabric softeners, metalworking fluids, antifouling paints, and fire-fighters. In addition, it offers Kolon BESFLOC polymer used in chemical, food, leather, pharmaceutical, textile, and dairy industries, as well as in settling reservoirs, sludge thickeners, floating reservoirs, and dehydrators in sewage treatment plants. The company was formerly known as Korea Tissuegene Asia, Ltd. and changed its name to Kolon Life Science Inc. in January 2006. Kolon Life Science Inc. was founded in 2000 and is headquartered in Seoul, South Korea.
Home Page: www.kolonls.co.kr
One & Only Tower
Seoul,
South Korea
Phone:
82 2 3677 4150
Officers
| Name | Title |
|---|---|
| Mr. Woo-Sok Lee | Chief Exec. Officer |
| Mr. Mun-Hee Park | Chief Exec. Officer |
| Mr. Tae-Hwan Kim | Pres |
| Sang-Jun Lee | Chief Operating Officer and Vice-Pres |
| Sang-Hu Park | Managing Director and Laboratory Director |
| Myung-Kwan Suh | Managing Director and Director of Management Support Division |
| Sang-Woo Lee | Managing Director and Director of Quality Management |
Exchange: KQ
Country: KR
Currency: Korean Won (₩)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 3.3242 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 422 |